M. Scot Roberts - Feb 2, 2023 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Scientific Officer
Signature: /s/ Richard Eisenstadt, as Attorney-in-Fact
Stock symbol: ALT
Transactions as of: Feb 2, 2023
Transactions value $: -$35,720
Form type: 4
Date filed: 2/6/2023, 03:31 PM
Previous filing: Feb 2, 2023
Next filing: Aug 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$0	+7.78K	+53.78%	$0.00	22.2K	Feb 2, 2023	Direct	F1
transaction	ALT	Common Stock, par value $0.0001	Tax liability	-$35.7K	-2.38K	-10.68%	$15.04	19.9K	Feb 2, 2023	Direct	F2
holding	ALT	Common Stock, par value $0.0001						15	Feb 2, 2023	Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Restricted Stock Units	Options Exercise	$0	-7.78K	-25%	$0.00	23.3K	Feb 2, 2023	Common Stock, par value $0.0001	7.78K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2	Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3	The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.